Prospective Randomized Controlled Trial of Extended-Release Oxybutynin Chloride and Tolterodine Tartrate in the Treatment of Overactive Bladder: Results of the OBJECT Study

Appell, Rodney A.; Sand, Peter K.; Dmochowski, Roger R.; Anderson, Rodney U.; Zinner, Norman R.; Lama, Daniel; Roach, Martha; Miklos, John R.; Saltzstein, Daniel R.; Boone, Timothy B.; Staskin, David R.; Albrecht, Detlef

doi:10.4065/76.4.358

Cited by 128 publications

(61 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overactive bladder affects more than 17 million people in the United States. It is more prevalent than asthma, osteoporosis, diabetes mellitus or AlzheimerÕs disease [1]. The cost of treating OAB is significant and sufferers experience a considerable impairment in quality of life.…”

Section: Introductionmentioning

confidence: 99%

Treatment of overactive bladder with botulinum toxin type B: a pilot study

Dykstra

Enriquez

Valley

2003

International Urogynecology Journal and Pelvic Floor Dysfunctio

View full text Add to dashboard Cite

The purpose of this study was to determine the efficacy and safety of botulinum toxin type B (BTX-B/Myobloc) in the treatment of patients with overactive bladder. This open-label dose-escalation study enrolled 15 female patients with urinary frequency with or without incontinence. The BTX-B doses used in this study were 2500, 3750, 5000, 10 000 and 15 000 units. Response was defined as a subjective improvement in frequency, urgency and incontinence symptoms. A paired t-test of the pre/post frequency difference indicates that these 15 patients experienced an average of 5.27 fewer frequency episodes per day after treatment with BTX-B. The p value for the paired t-test was <0.001. The longest duration effect was 3 months using 10 000-15 000 units of BTX-B. The correlation between dose and duration was very significant, with a correlation coefficient = 0.96, p<0.001. Based on these findings, we feel the use of botulinum toxin to treat patients with overactive bladder warrants further study.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment of overactive bladder with botulinum toxin type B: a pilot study

Dykstra

Enriquez

Valley

2003

International Urogynecology Journal and Pelvic Floor Dysfunctio

View full text Add to dashboard Cite

show abstract

“…The OBJECT trial [15] provided the first direct comparison of extended-release oxybutynin chloride and twice-daily tolterodine tartrate. At the time of the trial, Detrol LA, a once-daily extended-release formulation of was not yet available.…”

Section: Discussionmentioning

confidence: 99%

“…The OBJECT (Overactive Bladder: Judging Effective Control and Treatment) was the first comparative study of extended-release oxybutynin chloride and tolterodine tartrate [15]. The current evaluation is a subanalysis of the OBJECT data in women.…”

Section: Introductionmentioning

confidence: 99%

A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women

Sand

Miklos

Ritter

et al. 2003

International Urogynecology Journal and Pelvic Floor Dysfunctio

Self Cite

View full text Add to dashboard Cite

Women with urge or mixed incontinence were randomized to a daily dose of 10 mg extended-release oxybutynin chloride (qd) or tolterodine tartrate 4 mg (2 mg bid) for 12 weeks. Subjects completed 7-day voiding diaries at baseline and at 12 weeks. A total of 315 women were treated. At the end of the study, extended-release oxybutynin chloride was more effective than twice-daily tolterodine tartrate as measured by urge and total incontinence episodes (p=0.038, p=0.030, respectively). Overall, the reduction in micturition frequency between groups was not significantly different. In women aged 64 years and younger (comprising 63% of the population) extended-release oxybutynin was more effective than tolterodine for urge (p=0.005) and total incontinence (p=0.005), and for micturition frequency (0.024). Adverse events were infrequent, mostly mild, and similar between treatment groups. We concluded that daily extended-release oxybutynin chloride (10 mg) was more effective than tolterodine tartrate (2 mg bid) in treating urge and total incontinence. The incidences of dry mouth, CNS events, and other adverse events were similar for both drugs.

show abstract

“…Die Rate an Nebenwirkungen, insbesondere der Mundtrockenheit war bei beiden Substanzen vergleichbar [13].…”

Section: Neue Applikationsformen Des Oxybutyninunclassified

Pharmakotherapie der weiblichen Harninkontinenz

Szych

Dimpfl

2007

Gynäkologe

View full text Add to dashboard Cite

Die medikamentöse Therapie der Belastungsinkontinenz beschränkte sich lange Zeit auf die lokale Östrogenthe-rapie und die Anwendung von wenig erfolgreichen Substanzen. Seit 2004 steht für den klinischen Einsatz der kombinierte Serotonin-NoradrenalinReuptake-Hemmer Duloxetin zur Verfügung, dessen Wirksamkeit in placebokontrollierten Studien bewiesen wurde. Auch bei überaktiver Blase zeigen moderne, nebenwirkungsarme Anticholinergika, auch als transdermales System, oder alternativ die Injektion von Botulinumtoxin A hohe Wirksamkeit bei den Patientinnen. Effektive Pharmaka enttabuisieren das Volksleiden Harninkontinenz und verbessern die Compliance.

show abstract

Prospective Randomized Controlled Trial of Extended-Release Oxybutynin Chloride and Tolterodine Tartrate in the Treatment of Overactive Bladder: Results of the OBJECT Study

Cited by 128 publications

References 16 publications

Treatment of overactive bladder with botulinum toxin type B: a pilot study

Treatment of overactive bladder with botulinum toxin type B: a pilot study

A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women

Pharmakotherapie der weiblichen Harninkontinenz

Contact Info

Product

Resources

About